2. Search Result
Search Result
Results for "

Aromatase+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

2

Biochemical Assay Reagents

7

Natural
Products

7

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13632
    Exemestane
    Maximum Cited Publications
    7 Publications Verification

    FCE 24304; EXE

    		 Cytochrome P450 Endocrinology Cancer
    Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane
  • HY-14274
    Anastrozole
    4 Publications Verification

    ZD1033

    		 Cytochrome P450 Cancer
    Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM.
    Anastrozole
  • HY-B0845
    Prochloraz
    1 Publications Verification

    BTS 40542

    		 Environmental Pollutants Estrogen Receptor/ERR Aryl Hydrocarbon Receptor Fungal Androgen Receptor Infection Endocrinology
    Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an aromatase inhibitor with IC50 values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC50 of 1 μM .
    Prochloraz
  • HY-113986
    Dexfadrostat

    (R)-Fadrozole; (R)-CGS 16949A free base; FAD286

    		 Cytochrome P450 Cardiovascular Disease
    Dexfadrostat ((R)-Fadrozole) is an orally active and selective aromatase inhibitor, with human aromatase IC50 values of 6.4 nM. Dexfadrostat suppresses estrogen synthesis, reduces circulating estradiol levels and suppresses aldosterone production. Dexfadrostat can be used for the research of breast cancer, primary aldosteronism, and hypertension .
    Dexfadrostat
  • HY-N8487
    7-Methoxyflavone

    		Cytochrome P450 Neurological Disease Inflammation/Immunology Cancer
    7-Methoxyflavone is a flavonoid compound that can be isolated from Zornia brasiliensis. 7-Methoxyflavone can bind to human serum albumin and is an aromatase inhibitor. 7-Methoxyflavone has peripheral analgesic and certain antitumor activities. 7-Methoxyflavone is effective against chemical pain but has no significant effect on thermal pain .
    7-Methoxyflavone
  • HY-14274R
    Anastrozole (Standard)

    ZD1033 (Standard)

    		 Cytochrome P450 Reference Standards Cancer
    Anastrozole (Standard) is the analytical standard of Anastrozole. This product is intended for research and analytical applications. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM.
    Anastrozole (Standard)
  • HY-148430
    4-Pyridylmethyl adamantanecarboxamide

    		Cytochrome P450 Cancer
    4-Pyridylmethyl adamantanecarboxamide (Compound 11) is an Aromatase inhibitor with an IC50 of 1.5 μM against hAromatase. 4-Pyridylmethyl adamantanecarboxamide inhibits the C17,20-lyase activity of testicular cytochrome P45017α with an IC50 of 1600 nM, and also inhibits the 17α-hydroxylase activity of this enzyme with an IC50 of 7700 nM. 4-Pyridylmethyl adamantanecarboxamide can be used in the research of prostate cancer .
    4-Pyridylmethyl adamantanecarboxamide
  • HY-W010062
    4-Chlorophenylacetic acid

    		Drug Derivative Cytochrome P450 Estrogen Receptor/ERR Metabolic Disease Cancer
    4-Chlorophenylacetic acid is a halogenated phenylacetic acid derivative. 4-Chlorophenylacetic acid is a potent aromatase inhibitor and antagonizes estrogen signaling. 4-Chlorophenylacetic acid can provide carbon and energy for Pseudomonas sp. strain CBS3. 4-Chlorophenylacetic acid is effective against estrogen-induced mammary tumorigenesis .
    4-Chlorophenylacetic acid
  • HY-105184
    YM511

    		Cytochrome P450 Endocrinology
    YM511 is a highly specific non-steroidal aromatase inhibitor. YM511 inhibits aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s of 0.4 and 0.12 nM, respectively). YM511 slightly inhibits production of other steroid hormones. YM511 has the potential for suppressing estrogen-dependent action research without affecting serum levels of other steroid hormones .
    YM511
  • HY-W007664
    (R)-4-Benzyl-2-oxazolidinone

    		Drug Intermediate Cytochrome P450 Cancer
    (R)-4-Benzyl-2-oxazolidinone is an oxazolidinone-type auxiliary that enables highly stereoselective asymmetric alkylation reactions. (R)-4-Benzyl-2-oxazolidinone is applied in the total synthesis of natural products and pharmaceutical preparations. Especially in pharmaceutical research and development, (R)-4-Benzyl-2-oxazolidinone not only serves as a key precursor for the synthesis of aromatase inhibitors, but also can be used in studies related to estrogen-dependent breast cancer .
    (R)-4-Benzyl-2-oxazolidinone
  • HY-W392925
    (R)-(+)-Aminoglutethimide

    d-Aminoglutethimide

    		 Cytochrome P450 Cancer
    (R)-(+)-Aminoglutethimide is a potent and orally active aromatase inhibitor. (R)-(+)-Aminoglutethimide has the potential for the research of breast cancer .
    (R)-(+)-Aminoglutethimide
  • HY-14274S
    Anastrozole-d12

    ZD1033-d12

    		 Isotope-Labeled Compounds Cytochrome P450 Cancer
    Anastrozole-d12 is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM .
    Anastrozole-d12
  • HY-14247B
    Fadrozole hydrochloride hemihydrate
    2 Publications Verification

    CGS 16949A hemihydrate; (Rac)-FAD286 hydrochloride hemihydrate

    		 Cytochrome P450 Endocrinology Cancer
    Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal aromatase inhibitor, with an IC50 of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC50 values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer .
    Fadrozole hydrochloride hemihydrate
  • HY-13632R
    Exemestane (Standard)
    Maximum Cited Publications
    7 Publications Verification

    FCE 24304(Standard); EXE (Standard)

    		 Cytochrome P450 Reference Standards Endocrinology Cancer
    Exemestane (Standard) is the analytical standard of Exemestane. This product is intended for research and analytical applications. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane (Standard)
  • HY-N16402
    Aspergillusidone D

    		Cytochrome P450 Endogenous Metabolite Cancer
    Aspergillusidone D (Compound 1), a brominated depsidone, is a Aromatase inhibitor with an IC50 of 0.8  μM. Aspergillusidone D can be isolated from fungus Aspergillus unguis cultured in KBr medium. Aspergillusidone D has potent cytotoxicity against cancers cells, such as MOLT-3 cells. Aspergillusidone D can be used for cancers like breast cancer research .
    Aspergillusidone D
  • HY-137931
    Testololactone

    		Cytochrome P450 Cancer
    Testololactone is an aromatase inhibitor. Testololactone can be used for research of breast carcinoma .
    Testololactone
  • HY-179450
    Aromatase-IN-7

    		Cytochrome P450 Cancer
    Aromatase-IN-7 (compound 75) is a potent and selective aromatase inhibitor (IC50 = 5.78 nM), exhibiting potency comparable to Letrozole (HY-14248). Aromatase-IN-7 exhibits potent aromatase inhibition both in vitro and in vivo. Aromatase-IN-7 can be used for hormone-dependent breast cancer (HDBC) research .
    Aromatase-IN-7
  • HY-136092
    Androsta-1,4,6-triene-3,17-dione

    		Cytochrome P450 Neurological Disease Endocrinology
    Androsta-1,4,6-triene-3,17-dione is a lipophilic and specific aromatase inhibitor with a Ki of 0.18 μM. Androsta-1,4,6-triene-3,17-dione inhibits estrogen biosynthesis and shows antifertility effects. Androsta-1,4,6-triene-3,17-dione induces impairment of spatial memory .
    Androsta-1,4,6-triene-3,17-dione
  • HY-U00176
    Org30958

    		Cytochrome P450 Metabolic Disease
    Org30958 is a potent aromatase inhibitor in vivo.
    Org30958
  • HY-105375
    FR 901537

    		Cytochrome P450 Cancer
    FR 901537 is a potent and competitive aromatase inhibitor. FR 901537, a novel naphthol derivative, has the potential for breast cancer research .
    FR 901537
  • HY-159741
    Minamestane

    FCE 24928

    		 Cytochrome P450 Cancer
    Minamestane (FCE 24928) is a selective and competitive aromatase inhibitor with an IC50 value of 45.7 nM. Minamestane is promising for research of postmenopausal breast cancer .
    Minamestane
  • HY-19599A
    (Rac)-Vorozole

    (Rac)-R83842

    		 Cytochrome P450 Drug Isomer Others
    (Rac)-Vorozole ((Rac)-R83842) is a racemate of Vorozole. Vorozole (HY-19599) is a potent and selective, orally active non-steroidal aromatase inhibitor .
    (Rac)-Vorozole
  • HY-167737
    (-)-Vorozole

    		Cytochrome P450 Cancer
    (-)-Vorozole is an orally active non-steroidal aromatase inhibitor with potent and selective properties. (-)-Vorozole demonstrates antitumor activity in in vivo experiments. (-)-Vorozole is utilized in the study of breast cancer.
    (-)-Vorozole
  • HY-123247
    LY113174

    		Cytochrome P450 Endocrinology
    LY113174 is an orally active aromatase inhibitor (IC50 = 24 nM). LY113174 blocks testosterone induced increase in uterine weight in rat, and inhibits ovarian estrogen biosynthesis .
    LY113174
  • HY-19599
    Vorozole

    (+)-Vorozole; R83842

    		 Cytochrome P450 Cancer
    Vorozole is a potent and selective, orally active non-steroidal aromatase inhibitor . Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer .
    Vorozole
  • HY-113986B
    (S)-Dexfadrostat

    (S)-Fadrozole; (S)-CGS 16949A free base; (S)-FAD286

    		 Cytochrome P450 Inflammation/Immunology Endocrinology Cancer
    (S)-Dexfadrostat ((S)-Fadrozole) is an aromatase inhibitor with an IC50 of 4.6 nM in human placental microsomes in vitro. (S)-Dexfadrostat can be used in the study of estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus .
    (S)-Dexfadrostat
  • HY-N3246
    Morachalcone A

    		NO Synthase Inflammation/Immunology
    Morachalcone A is a naturally-occurring aromatase inhibitor (IC50=4.6 mM). Morachalcone A is also a plants metabolite with potential anti-inflammatory and anticancer activity. Morachalcone A inhibits Lipopolysaccharide (HY-D1056)-induced nitric oxide production .
    Morachalcone A
  • HY-13632S
    Exemestane-d2

    FCE 24304-d2; EXE-d2

    		 Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d2 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-d2
  • HY-162105
    Aromatase-IN-3

    		Cytochrome P450 Endocrinology Cancer
    Aromatase-IN-3 (compound 7d) is an aromatase inhibitor with an IC50 of 54 nM. Through suppressing the conversion of androstenedione to oestrogen caused by aromatase, Aromatase-IN-3 exerts an appreciable tumor growth inhibitory activities against breast cancer cell lines, suggesting its usage for ER+ cancer research .
    Aromatase-IN-3
  • HY-13632S2
    Exemestane-d3

    FCE 24304-d3; EXE-d3

    		 Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d3 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-d3
  • HY-118178
    LY43578

    		Cytochrome P450 Monoamine Oxidase Cardiovascular Disease
    LY43578 is an orally active aromatase inhibitor. LY43578 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC50 of 0.3 and 5 μΜ, respectively. LY43578 can be used for neurological disorder study .
    LY43578
  • HY-118407
    LY56110

    		Cytochrome P450 Monoamine Oxidase Neurological Disease
    LY56110 is an orally active aromatase inhibitor. LY56110 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC50 of 2.5 and 11 μΜ, respectively. LY56110 can be used for neurological disorder study .
    LY56110
  • HY-13632S1
    Exemestane-13C3

    FCE 24304-13C3; EXE-13C3

    		 Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane- 13C3 is the 13C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-13C3
  • HY-W699238
    S-(-)-Aminoglutethimide D-tartrate

    		Biochemical Assay Reagents
    S-(-)-Aminoglutethimide D-tartrate is an aromatase inhibitor with activity that blocks adrenal steroidogenesis. S-(-)-Aminoglutethimide D-tartrate can be used to inhibit steroid-related diseases. S-(-)-Aminoglutethimide D-tartrate is often used clinically to control certain types of cancer. S-(-)-Aminoglutethimide D-tartrate effectively reduces testosterone and estrogen levels through an enzyme inhibition mechanism.
    S-(-)-Aminoglutethimide D-tartrate
  • HY-13632S6
    Exemestane-d4

    FCE 24304-d4; EXE-d4

    		 Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d4 (FCE 24304-d4) is deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-d4
  • HY-13632S5
    Exemestane-13C,d2

    FCE 24304-13C,d2; EXE-13C,d2

    		 Cytochrome P450 Isotope-Labeled Compounds Endocrinology Cancer
    Exemestane- 13C,d2 is 13C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-13C,d2
  • HY-B0845R
    Prochloraz (Standard)

    BTS 40542 (Standard)

    		 Reference Standards Fungal Estrogen Receptor/ERR Androgen Receptor Aryl Hydrocarbon Receptor Infection Endocrinology
    Prochloraz (Standard) is the analytical standard of Prochloraz. This product is intended for research and analytical applications. Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an aromatase inhibitor with IC50 values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC50 of 1 μM .
    Prochloraz (Standard)
  • HY-W010062R
    4-Chlorophenylacetic acid (Standard)

    		Reference Standards Cytochrome P450 Estrogen Receptor/ERR Drug Derivative Metabolic Disease Cancer
    4-Chlorophenylacetic acid (Standard) is the analytical standard of 4-Chlorophenylacetic acid. This product is intended for research and analytical applications. 4-Chlorophenylacetic acid is a halogenated phenylacetic acid derivative. 4-Chlorophenylacetic acid is a potent aromatase inhibitor and antagonizes estrogen signaling. 4-Chlorophenylacetic acid can provide carbon and energy for Pseudomonas sp. strain CBS3. 4-Chlorophenylacetic acid is effective against estrogen-induced mammary tumorigenesis .
    4-Chlorophenylacetic acid (Standard)
  • HY-W716464
    Prochloraz-d7

    BTS 40542-d7

    		 Isotope-Labeled Compounds Fungal Aryl Hydrocarbon Receptor Estrogen Receptor/ERR Androgen Receptor Infection
    Prochloraz-d7 (BTS 40542-d7) is the deuterium labeled Prochloraz (HY-B0845). Prochloraz is an imidazole antifungal. Prochloraz is as an estrogen receptor (ER) and androgen receptor (AR) antagonist and an aromatase inhibitor with IC50 values of 25 μM, 4 μM and 0.3 μM, respectively. Prochloraz is able to activate the aryl hydrocarbon receptor (AhR) having an EC50 of 1 μM .
    Prochloraz-d7
  • HY-138089
    17β-Hydroxy exemestane

    		Androgen Receptor Estrogen Receptor/ERR LDLR Metabolic Disease Cancer
    17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .
    17β-Hydroxy exemestane
  • HY-106750
    Rogletimide

    		Cytochrome P450 Cancer
    Rogletimide is an aromatase inhibitor. Rogletimide can be studied in research on cancer .
    Rogletimide
  • HY-W141312
    5α-Androst-2-en-17-one

    		Cytochrome P450 Others
    5α-Androst-2-en-17-one, a steroid, is an aromatase inhibitor.
    5α-Androst-2-en-17-one
  • HY-W393057
    (S)-Aminoglutethimide

    		Cytochrome P450 Cancer
    (S)-Aminoglutethimide is an aromatase inhibitor. (S)-Aminoglutethimide has an IC50 value of 23.15 μM for rat ovarian microsomal aromatase. (S)-Aminoglutethimide can be used in the research of diseases such as breast cancer .
    (S)-Aminoglutethimide
  • HY-109062
    CGP 47645

    BGS-649

    		 Cytochrome P450 Others
    CGP 47645 is a long-acting nonsteroidal aromatase inhibitor. CGP 47645 can significantly affect testicular function. CGP 47645 can be used to study the physiological role of estrogen in regulating testicular function .
    CGP 47645
  • HY-182708
    CGS 18320B

    		Cytochrome P450 Metabolic Disease
    CGS 18320B is a human placental microsomal aromatase inhibitor with a Ki of 0.16 nM. CGS 18320B interacts reversibly with the enzyme's active site to block estrogen biosynthesis from androstenedione. CGS 18320B can be used for the research of aromatase inhibition and estrogen biosynthesis regulation .
    CGS 18320B
  • HY-182498
    (Z)-Norendoxifen

    		Cytochrome P450 Estrogen Receptor/ERR Cancer
    (Z)-Norendoxifen is an aromatase inhibitor and estrogen receptor modulator. The IC50 value of (Z)-Norendoxifen against aromatase is 102 nM. The EC50 values of (Z)-Norendoxifen for ER-α and ER-β are 27.0 nM and 35.2 nM, respectively. (Z)-Norendoxifen can be used in breast cancer research .
    (Z)-Norendoxifen
  • HY-113986C
    Dexfadrostat hydrochloride

    (R)-Fadrozole hydrochloride; (R)-CGS 16949A; FAD286 hydrochloride

    		 Cytochrome P450 Cardiovascular Disease Cancer
    Dexfadrostat ((R)-Fadrozole) hydrochloride is an orally active and selective aromatase inhibitor, with human aromatase IC50 values of 6.4 nM. Dexfadrostat hydrochloride suppresses estrogen synthesis, reduces circulating estradiol levels and suppresses aldosterone production. Dexfadrostat hydrochloride can be used for the research of breast cancer, primary aldosteronism, and hypertension .
    Dexfadrostat hydrochloride
  • HY-123278
    FUB 349

    		Cytochrome P450 Histamine Receptor Neurological Disease
    FUB 349 (Compound 8) is a selective Aromatase inhibitor with an IC50 of 12  μM. FUB 349 is also a H3 receptor antagonist with Kis of 12 and 2.1 nM for rH3R and hH3R, respectively. FUB 349 can be used for neurological diseases such as cognitive impairment research .
    FUB 349
  • HY-180535
    Aromatase-IN-8

    		Cytochrome P450 Cancer
    Aromatase-IN-8 is a selective Aromatase inhibitor against an IC50 of 0.05 µM. Aromatase-IN-8 exhibits selective antiproliferative effects against estrogen receptor-positive breast cancer cell lines, while showing no toxicity toward non-tumoral cells. Aromatase-IN-8 suppresses estrogen active, increases testosterone levels, and downregulates estrogen receptor expression and phosphorylation. Aromatase-IN-8 can be used for triple negative breast cancer research .
    Aromatase-IN-8
  • HY-123500
    CGP-45688

    		Cytochrome P450 Cancer
    CGP-45688 is an orally active non-steroidal aromatase inhibitor with an ED50 of 30-100 μg/kg. CGP-45688 can reduce the level of estrogen in the body, thereby inhibiting the growth of estrogen-dependent tumors. CGP-45688 inhibits the growth of estrogen-dependent breast tumors in rat models. CGP-45688 disrupts the ovarian cycle and inhibits the weight of the uterus. CGP-45688 can be used for the study of breast cancer .
    CGP-45688

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: